Do analysts recommend SLGL or DRCT?

Sol-Gel Technologies currently has a consensus target price of $197.50, indicating a potential upside of 180.94%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe Sol-Gel Technologies is more favorable than Direct Digital. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sol-Gel Technologies 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 Direct Digital 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer SLGL or DRCT?

In the previous week, Direct Digital had 1 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 6 mentions for Direct Digital and 5 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 1.95 beat Direct Digital's score of -0.82 indicating that Sol-Gel Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sol-Gel Technologies 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Direct Digital 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media prefer SLGL or COLL?

In the previous week, Collegium Pharmaceutical had 4 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 9 mentions for Collegium Pharmaceutical and 5 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 1.95 beat Collegium Pharmaceutical's score of 0.87 indicating that Sol-Gel Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sol-Gel Technologies 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Collegium Pharmaceutical 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SGP or SLGL?

In the previous week, Sol-Gel Technologies had 3 more articles in the media than Spyglass Pharma. MarketBeat recorded 5 mentions for Sol-Gel Technologies and 2 mentions for Spyglass Pharma. Sol-Gel Technologies' average media sentiment score of 1.95 beat Spyglass Pharma's score of 0.67 indicating that Sol-Gel Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyglass Pharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sol-Gel Technologies 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to SLGL or TBPH?

In the previous week, Sol-Gel Technologies and Sol-Gel Technologies both had 5 articles in the media. Sol-Gel Technologies' average media sentiment score of 1.95 beat Theravance Biopharma's score of 1.35 indicating that Sol-Gel Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sol-Gel Technologies 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Theravance Biopharma 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sol-Gel Technologies (SLGL) Competitors

$70.30 -0.13 (-0.18%)

As of 02:39 PM Eastern

Compare

SLGL vs. DRCT, TRAW, COLL, SGP, and TBPH

Should you buy Sol-Gel Technologies stock or one of its competitors? Sol-Gel Technologies's main competitors and comparable companies include Direct Digital (DRCT), Traws Pharma (TRAW), Collegium Pharmaceutical (COLL), Spyglass Pharma (SGP), and Theravance Biopharma (TBPH). Companies are selected based on similarities in market, industry, and size.

How does Sol-Gel Technologies compare to Direct Digital?

Sol-Gel Technologies (NASDAQ:SLGL) and Direct Digital (NASDAQ:DRCT) are related small-cap companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Sol-Gel Technologies currently has a consensus target price of $197.50, indicating a potential upside of 180.94%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe Sol-Gel Technologies is more favorable than Direct Digital.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Direct Digital	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Sol-Gel Technologies has higher earnings, but lower revenue than Direct Digital. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Direct Digital, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	10.19	-$6.13M	-$5.64	N/A
Direct Digital	$30.91M	0.05	-$18.95M	-$156.85	N/A

26.2% of Sol-Gel Technologies shares are owned by institutional investors. Comparatively, 4.0% of Direct Digital shares are owned by institutional investors. 66.5% of Sol-Gel Technologies shares are owned by company insiders. Comparatively, 25.6% of Direct Digital shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Direct Digital has a net margin of -74.38% compared to Sol-Gel Technologies' net margin of -910.14%. Direct Digital's return on equity of 0.00% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%
Direct Digital	-74.38%	N/A	-68.48%

Sol-Gel Technologies has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Direct Digital has a beta of 5.3, meaning that its stock price is 430% more volatile than the broader market.

In the previous week, Direct Digital had 1 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 6 mentions for Direct Digital and 5 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 1.95 beat Direct Digital's score of -0.82 indicating that Sol-Gel Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sol-Gel Technologies	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Direct Digital	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Sol-Gel Technologies beats Direct Digital on 11 of the 17 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Traws Pharma?

Sol-Gel Technologies (NASDAQ:SLGL) and Traws Pharma (NASDAQ:TRAW) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Sol-Gel Technologies has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market.

In the previous week, Sol-Gel Technologies had 5 more articles in the media than Traws Pharma. MarketBeat recorded 5 mentions for Sol-Gel Technologies and 0 mentions for Traws Pharma. Sol-Gel Technologies' average media sentiment score of 1.95 beat Traws Pharma's score of 0.00 indicating that Sol-Gel Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Sol-Gel Technologies	Very Positive
Traws Pharma	Neutral

26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 8.0% of Traws Pharma shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by company insiders. Comparatively, 7.6% of Traws Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Sol-Gel Technologies currently has a consensus target price of $197.50, suggesting a potential upside of 180.94%. Traws Pharma has a consensus target price of $1.00, suggesting a potential upside of 81.29%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, equities research analysts clearly believe Sol-Gel Technologies is more favorable than Traws Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Traws Pharma	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Traws Pharma has lower revenue, but higher earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	10.19	-$6.13M	-$5.64	N/A
Traws Pharma	$2.79M	3.04	$9.17M	-$1.74	N/A

Traws Pharma has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -910.14%. Sol-Gel Technologies' return on equity of -44.05% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%
Traws Pharma	N/A	-23,868.92%	-165.52%

Summary

Sol-Gel Technologies beats Traws Pharma on 12 of the 17 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Collegium Pharmaceutical?

Sol-Gel Technologies (NASDAQ:SLGL) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

Sol-Gel Technologies has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market.

Collegium Pharmaceutical has higher revenue and earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	10.19	-$6.13M	-$5.64	N/A
Collegium Pharmaceutical	$780.57M	1.00	$62.87M	$1.24	19.34

In the previous week, Collegium Pharmaceutical had 4 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 9 mentions for Collegium Pharmaceutical and 5 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 1.95 beat Collegium Pharmaceutical's score of 0.87 indicating that Sol-Gel Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sol-Gel Technologies	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Collegium Pharmaceutical	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Sol-Gel Technologies presently has a consensus price target of $197.50, suggesting a potential upside of 180.94%. Collegium Pharmaceutical has a consensus price target of $51.00, suggesting a potential upside of 112.68%. Given Sol-Gel Technologies' higher possible upside, analysts plainly believe Sol-Gel Technologies is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Collegium Pharmaceutical	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71

26.2% of Sol-Gel Technologies shares are owned by institutional investors. 66.5% of Sol-Gel Technologies shares are owned by insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Collegium Pharmaceutical has a net margin of 5.93% compared to Sol-Gel Technologies' net margin of -910.14%. Collegium Pharmaceutical's return on equity of 91.43% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%
Collegium Pharmaceutical	5.93%	91.43%	15.57%

Summary

Collegium Pharmaceutical beats Sol-Gel Technologies on 9 of the 15 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Spyglass Pharma?

Spyglass Pharma (NASDAQ:SGP) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Spyglass Pharma has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -910.14%. Sol-Gel Technologies' return on equity of -44.05% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	-62.40%	-24.83%
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%

26.2% of Sol-Gel Technologies shares are owned by institutional investors. 66.5% of Sol-Gel Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Sol-Gel Technologies had 3 more articles in the media than Spyglass Pharma. MarketBeat recorded 5 mentions for Sol-Gel Technologies and 2 mentions for Spyglass Pharma. Sol-Gel Technologies' average media sentiment score of 1.95 beat Spyglass Pharma's score of 0.67 indicating that Sol-Gel Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyglass Pharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sol-Gel Technologies	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Spyglass Pharma presently has a consensus price target of $44.00, indicating a potential upside of 51.25%. Sol-Gel Technologies has a consensus price target of $197.50, indicating a potential upside of 180.94%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Sol-Gel Technologies is more favorable than Spyglass Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Sol-Gel Technologies has higher revenue and earnings than Spyglass Pharma. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A
Sol-Gel Technologies	$19.39M	10.19	-$6.13M	-$5.64	N/A

Summary

Sol-Gel Technologies beats Spyglass Pharma on 11 of the 15 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Theravance Biopharma?

Sol-Gel Technologies (NASDAQ:SLGL) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

Sol-Gel Technologies presently has a consensus target price of $197.50, indicating a potential upside of 180.94%. Theravance Biopharma has a consensus target price of $19.40, indicating a potential upside of 13.58%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Sol-Gel Technologies is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Theravance Biopharma	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.25

In the previous week, Sol-Gel Technologies and Sol-Gel Technologies both had 5 articles in the media. Sol-Gel Technologies' average media sentiment score of 1.95 beat Theravance Biopharma's score of 1.35 indicating that Sol-Gel Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sol-Gel Technologies	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Theravance Biopharma	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by company insiders. Comparatively, 7.7% of Theravance Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Sol-Gel Technologies has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

Theravance Biopharma has a net margin of 51.58% compared to Sol-Gel Technologies' net margin of -910.14%. Theravance Biopharma's return on equity of -0.77% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%
Theravance Biopharma	51.58%	-0.77%	-0.46%

Theravance Biopharma has higher revenue and earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	10.19	-$6.13M	-$5.64	N/A
Theravance Biopharma	$107.46M	8.25	$105.89M	$1.01	16.91

Summary

Theravance Biopharma beats Sol-Gel Technologies on 8 of the 15 factors compared between the two stocks.

Get Sol-Gel Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLGL vs. The Competition

Export

Metric	Sol-Gel Technologies	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$197.54M	$12.33B	$7.26B	$12.91B
Dividend Yield	N/A	2.60%	2.53%	8.56%
P/E Ratio	-12.46	789.77	273.83	25.42
Price / Sales	10.19	957.01	676.21	123.96
Price / Cash	N/A	92.66	76.98	52.08
Price / Book	4.11	12.38	12.89	6.17
Net Income	-$6.13M	$2.83B	$3.48B	$349.24M
7 Day Performance	-3.13%	2.24%	-0.36%	-1.42%
1 Month Performance	-14.26%	5.06%	6.49%	2.53%
1 Year Performance	200.43%	9.35%	25.06%	15.84%

Sol-Gel Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLGL Sol-Gel Technologies	4.1279 of 5 stars	$70.30 -0.2%	$197.50 +180.9%	+201.2%	$197.54M	$19.39M	N/A	50	Analyst Forecast Insider Trade
DRCT Direct Digital	0.9327 of 5 stars	$2.30 -2.1%	N/A	-98.1%	$1.71M	$30.91M	N/A	60	Analyst Revision
TRAW Traws Pharma	1.7528 of 5 stars	$0.58 +3.4%	$1.00 +72.8%	-60.4%	$8.90M	$2.79M	N/A	17	Gap Up
COLL Collegium Pharmaceutical	3.0089 of 5 stars	$27.47 +0.4%	$51.00 +85.7%	-37.9%	$894.42M	$780.57M	22.15	210
SGP Spyglass Pharma	2.0484 of 5 stars	$26.60 +1.3%	$44.00 +65.4%	N/A	$889.32M	N/A	N/A	65	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLGL) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sol-Gel Technologies (SLGL) Competitors

SLGL vs. DRCT, TRAW, COLL, SGP, and TBPH

How does Sol-Gel Technologies compare to Direct Digital?

Summary

How does Sol-Gel Technologies compare to Traws Pharma?

Summary

How does Sol-Gel Technologies compare to Collegium Pharmaceutical?

Summary

How does Sol-Gel Technologies compare to Spyglass Pharma?

Summary

How does Sol-Gel Technologies compare to Theravance Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLGL vs. The Competition

Sol-Gel Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sol-Gel Technologies (SLGL) Competitors

SLGL vs. DRCT, TRAW, COLL, SGP, and TBPH

How does Sol-Gel Technologies compare to Direct Digital?

Do analysts recommend SLGL or DRCT?

Which has preferable earnings and valuation, SLGL or DRCT?

Do institutionals & insiders have more ownership in SLGL or DRCT?

Is SLGL or DRCT more profitable?

Which has more volatility & risk, SLGL or DRCT?

Does the media prefer SLGL or DRCT?

Summary

How does Sol-Gel Technologies compare to Traws Pharma?

Which has more risk & volatility, SLGL or TRAW?

Does the media prefer SLGL or TRAW?

Do institutionals and insiders believe in SLGL or TRAW?

Do analysts rate SLGL or TRAW?

Which has stronger valuation & earnings, SLGL or TRAW?

Is SLGL or TRAW more profitable?

Summary

How does Sol-Gel Technologies compare to Collegium Pharmaceutical?

Which has more volatility and risk, SLGL or COLL?

Which has preferable earnings and valuation, SLGL or COLL?

Does the media prefer SLGL or COLL?

Do analysts prefer SLGL or COLL?

Do insiders and institutionals hold more shares of SLGL or COLL?

Is SLGL or COLL more profitable?

Summary

How does Sol-Gel Technologies compare to Spyglass Pharma?

Is SGP or SLGL more profitable?

Do insiders & institutionals believe in SGP or SLGL?

Does the media favor SGP or SLGL?

Do analysts recommend SGP or SLGL?

Which has higher valuation & earnings, SGP or SLGL?

Summary

How does Sol-Gel Technologies compare to Theravance Biopharma?

Do analysts rate SLGL or TBPH?

Does the media refer more to SLGL or TBPH?

Do institutionals and insiders have more ownership in SLGL or TBPH?

Which has more risk & volatility, SLGL or TBPH?

Is SLGL or TBPH more profitable?

Which has higher valuation and earnings, SLGL or TBPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLGL vs. The Competition

Sol-Gel Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools